Boehringer Ingelheim
Boehringer Ingelheim Gmbh
Pharmavitae Profile
| Publication Date | December 2007 |
| Publisher | Datamonitor |
| Product Type | Report |
| Pages | 96 |
| ISBN Number | not applicable |
| Product Code | DAT01126 |
Price
£1,990.00
approximately: $3,013 | €2,221
approximately: $3,013 | €2,221
print £2,010 ($3,043 | €2,243)
Order above formats by FAX
Summary
Introduction
This analysis examines the historical and forecast performance for Boehringer Ingelheim in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Boehringer Ingelheim's performance against key rivals in the ethical pharmaceutical sector
- Analyze how the asthma and COPD therapy Spiriva will act as the key driver of Boehringer Ingelheim's commercial performance out to 2012
- Assess Boehringer Ingelheim's narrow therapeutic focus and the potential barrier to sales growth that this will provide
Contents
- Introduction
- This Analysis Examines The Historical And Forecast Performance For Boehringer Ingelheim In The Ethical Pharma Sector. The Profile Encompasses Global Company Strategy, Portfolio And Pipeline Analysis And Assessment Of Financial Performance, With 1-6 Year Sales Forecasts For Key Drugs. An Interactive Forecasting And Analysis Tool Provides Continually Updated Quantitative And Qualitative Information.
- Scope
- Highlights
- Reasons To Purchase
- Benchmark Boehringer Ingelheim's Performance Against Key Rivals In The Ethical Pharmaceutical Sector Analyze How The Asthma And Copd Therapy Spiriva Will Act As The Key Driver Of Boehringer Ingelheim's Commercial Performance Out To 2012 Assess Boehringer Ingelheim's Narrow Therapeutic Focus And The Potential Barrier To Sales Growth That This Will Provide.
